MAP3K13

Across TCGA pan-cancer cohorts, MAP3K13 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP3K13 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MAP3K13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and OV are the cancer types where MAP3K13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.127	0.801	<.001	42	view →
UCEC	DFS	Median	All	0.949	0.603	.002	22	view →
OV	DFS	Median	II,III,IV	0.271	0.542	.020	18	view →
BLCA	DFS	Median	All	0.260	0.525	.030	12	view →
PRAD	DFS	Median	All	0.617	0.886	.013	6	view →
SKCM	DFS	Median	IV	0.016	0.454	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP3K13–CESC (OS)

Open the CESC breakdown →